Synthetic Peptides Suppress Nervous Necrosis Virus Absorption and Improve Survival Rates in European Sea Bass

Abstract

With few preventive strategies available against nodavirus (NNV) in aquaculture, therapeutic applications remain underexplored. This study aimed to peptide-based treatments disrupting critical stages of its viral life cycle. Thus, we designed and synthesized seven low-molecular-weight peptides (P1–P7) based on predicted binding regions of the capsid protein from the red-spotted grouper nervous necrosis virus (RGNNV) genotype to mimic viral capsid regions. Although in silico predictions suggested limited direct antiviral activity, in vitro assays using the E-11 cell line and in vivo trials in RGNNV-infected European sea bass (Dicentrarchus labrax) juveniles yielded promising results. The peptides, particularly when co-administered individually or as P3 + P4 and P5 + P6 combinations with the virus, disrupted RGNNV attachment in vitro. Moreover, they exhibited cross-reactivity against the striped jack nervous necrosis virus (SJNNV) genotype and both RGNNV/SJNNV and SJNNV/RGNNV reassortants. Treatment of RGNNV-infected sea bass significantly increased the relative percent survival, ranging from 81.3% for P4 to 62.5% for P3 and P3 + P4, while reducing viral load within 48 h post-treatment without altering systemic antiviral immune responses, tested through the transcriptional levels of mx gene in the head-kidney. Notably, peptide P4 partially inhibited viral replication in vitro at the same time-point when cells were pre-treated for 24 h, likely through modulation of host immune responses. These findings highlight the potential of targeted peptide-based therapies as a promising antiviral therapeutic strategy against NNV infections.